Compare Abbott Laboratories (ABT) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Abbott Laboratories trades at $111.09 (market cap $187.95B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.31. The key difference: Abbott Laboratories pays a 2.32% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals.
| ABT | QCLN | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $68.47 |
52-Week Low | $82.57 | $36.11 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
QCLN trades at $53.17, up 2.15% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights clean energy ETF growth driven by data center demand and geopolitical shifts, though regulatory hurdles and supply chain costs pose challenges. The stock lacks disclosed financial ratios, requiring deeper fundamental review.
Outlook is cautiously optimistic given sector tailwinds, but investment hinges on policy stability and cost management. Risks include U.S. permit delays and Chinese trade tensions, while institutional sentiment appears mixed amid volatile clean energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
